Rio Tinto Posts Strong Q4 Iron Ore and Copper Output on Operational Recovery 
Global DRAM Chip Shortage Puts Automakers Under New Cost and Supply Pressure 
Brazil Supreme Court Orders Asset Freeze of Nelson Tanure Amid Banco Master Investigation 
Netflix Stock Slips After Earnings as Soft 2026 Guidance Overshadows Subscriber Milestone 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Trump Criticizes NYSE Texas Expansion, Calls Dallas Exchange a Blow to New York 
Elon Musk Says Tesla Cybercab and Optimus Production Will Start Slowly Before Rapid Growth 
Lululemon Founder Chip Wilson Escalates Proxy Fight to Remove Advent From Board 
OpenAI Launches Stargate Community Plan to Offset Energy Costs and Support Local Power Infrastructure 
Micron to Buy Powerchip Fab for $1.8 Billion, Shares Surge Nearly 10% 
Valentino Garavani Dies at 93, Leaving Behind the Timeless Legacy of Valentino Red 
White House Pressures PJM to Act as Data Center Energy Demand Threatens Grid Reliability 
Trump Signs Executive Order to Limit Wall Street Investment in Single-Family Homes 
Baidu Shares Rise in Hong Kong After Apollo Go Robotaxi Launch in Abu Dhabi 
Nvidia CEO Jensen Huang Plans China Visit Amid AI Chip Market Uncertainty 
Proposed Rio Tinto–Glencore Merger Faces China Regulatory Hurdles and Asset Sale Pressure 
SYDNEY, Australia, April 28, 2017 -- Parnell Pharmaceuticals Holdings Ltd (OTC:PARNF), a fully integrated, commercial-stage pharmaceutical company focused on developing, manufacturing and marketing innovative animal health solutions, provides notice of its Annual General Meeting to be held Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)
NOTICE OF ANNUAL GENERAL MEETING AND EXPLANATORY MEMORANDUM
Notice is given that the Annual General Meeting of shareholders of Parnell Pharmaceuticals Holdings Ltd (Company) will be held on:
Monday 29 May 2017 at 4:00 p.m. (Central Standard Time) and Tuesday 30 May 2017 at 7:00 a.m. (Australian Eastern Standard Time)
Meeting to be held by teleconference (Dial-in details below):
| United States | 1 800 444 2801 | |
| Australia | 02 9037 8402 | |
| New Zealand | 0 800 440 176 | |
| Switzerland | 0800 564 606 | |
| Netherlands | 8000 220 915 | |
| United Kingdom | 0 800 234 6984 | |
| Hong Kong | 800 903 191 | |
| Participant Code: 5687312 | ||
For a link to the full Notice of Annual General Meeting and Explanatory Memorandum please click:
http://www.globenewswire.com/NewsRoom/AttachmentNg/9bf785e5-da8b-4b60-a5d2-d71ace68e95e
______________________
26 April 2017
Dear Shareholder,
On behalf of the Board of Directors of Parnell Pharmaceuticals Holdings Limited (ACN 137 904 413) (Company), I invite you to join us at our Annual General Meeting (AGM), which has been scheduled as follows:
| Date: | 29 May 2017 (CST), 30 May 2017 (AEST) | |
| Time: | 4:00 p.m. (CST), 7:00 a.m. (AEST) | |
| Venue: | Held by telephone conference (dial-in details above) or by physical attendance at: | |
| Unit 4 Century Estate, 476 Gardeners Road, Alexandria, NSW, 2015 |
Outline of the items of business
At this AGM, we will provide an opportunity for shareholders to consider the following:
- the Company’s financial statements and related documents;
- ratification of the appointment of the Company auditor; and
- re-election of Dr. Alan Bell as a director of the Company.
Details of these items are contained in the enclosed Notice of AM and Explanatory Memorandum.
Voting at the AGM or by proxy
A proxy form accompanies the enclosed Notice of AGM. If you wish to attend the AGM in person, please bring a copy of the proxy form with you. Registration will be available from 3:30 p.m. (CST). If you are unable to attend in person, I encourage you to appoint a proxy to vote on the resolutions contained in the Notice of AGM on your behalf, by completing and returning the enclosed proxy form. Details of how to submit the proxy form are included with the form.
On behalf of all of the Directors, we look forward to hearing from you at the AGM.
Yours sincerely,
Alan Bell
Chairman
For more information, contact: Parnell Pharmaceuticals Holdings Robert Joseph, 913-274-2100 [email protected] Brad McCarthy, 913-274-2100 [email protected]
